Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).

No abstract is available for this paper.

• Publication year

  2007

• Venue

  American Journal of Cardiology

• Publication date

  2007-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AMJCARD.2006.10.068PMID 17398202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes.

  2006cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

  2005cited by this paper
• Standards of medical care in diabetes.

  2005cited by this paper
• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri

  2005cited by this paper
• Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.

  2005cited by this paper
• Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

  2004cited by this paper
• Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.

  2004cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Diet, nutrition and the prevention of type 2 diabetes

  2004cited by this paper
• Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

  2004cited by this paper
• XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

  2004cited by this paper
• Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome

  2004cited by this paper
• A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

  2003cited by this paper
• Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

  2003cited by this paper
• Economic costs of diabetes in the US in 2002.

  2003cited by this paper
• Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)

  2003cited by this paper
• The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

  2003cited by this paper
• Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease.

  2003cited by this paper
• Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure: Insight From the Studies Of Left Ventricular Dysfunction (SOLVD)

  2003cited by this paper
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  2003cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• Helping patients follow prescribed treatment: clinical applications.

  2002cited by this paper
• Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

  2001cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient

  1999cited by this paper
• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

  1999cited by this paper
• Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

  1999cited by this paper
• Renoprotection and renin-angiotensin system blockade in diabetes mellitus.

  1997cited by this paper
• Selecting and Appraising Studies for a Systematic Review

  1997cited by this paper
• Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.

  1995cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Retrospective analysis of influences of sacubitril/valsartan in patients with diabetes with poorly controlled blood pressure in Japan

  2025cites this paper
• Cardiometabolic Dysregulation and Heart Failure

  2025cites this paper
• Molecular Dissection of the Role of ACE2 in Glucose Homeostasis.

  2025cites this paper
• Soluble (Pro)Renin Receptor Level in Patients with Severe Obesity Is Associated with Visceral Adiposity and Is Involved with Insulin Resistance and Renal Injury

  2023cites this paper
• Novel Diabetic Nephropathy-Based Hypertension Treatment for Type-2 Diabetes Mellitus and CKD Patients: A Mini Review

  2023cites this paper
• Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure

  2023cites this paper
• Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism

  2022cites this paper
• Deciphering the link between Diabetes mellitus and SARS-CoV-2 infection through differential targeting of microRNAs in the human pancreas

  2021cites this paper
• Vitamin D, renin-angiotensin system, and COVID-19: their importance in diabetes

  2021cites this paper
• Relationship of plasma aldosterone levels and carbohydrate metabolism in heart failure with preserved ejection fraction

  2021cites this paper
• Angiotensin‐converting enzyme inhibitors versus angiotensin receptor blockers: New‐onset diabetes mellitus stratified by statin use

  2021cites this paper
• Diabetes and COVID-19: Role of insulin resistance as a risk factor for COVID-19 severity

  2021cites this paper
• Case series: COVID-19 infection causing new-onset diabetes mellitus?

  2021cites this paper
• INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"

  2021cites this paper
• Non-coding Single Nucleotide Variants of Renin and the (Pro)renin Receptor are Associated with Polygenic Diseases in a Bangladeshi Population

  2021cites this paper
• Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives

  2021cites this paper
• Diabetogenic effects of cardioprotective drugs

  2020cites this paper
• Efficiency (advantages) of ramipril in arterial hypertension and diabetes mellitus from the point of view of evidence-based medicine

  2020cites this paper
• Антиоксидантная терапия последствий ишемических инсультов, с позиции доказательной медицины

  2020cites this paper
• Comparison between calcium channel blocker with angiotensin converting enzyme inhibitor or angiotensin II type 1 receptor blocker combination on the development of new-onset diabetes in hypertensive Korean patients

  2020cites this paper
• Effect of insulin and captopril on diabetic cardiomyopathy in adult male albino rat: Histological, biochemical and pharmacological study

  2020cites this paper
• ANGIOTENSIN CONVERTING ENZYME INHIBITION: A MODIFYING PLAYER ON ATHEROGENESIS IN HEMODIALYSIS PATIENTS WITH HEPATITIS C INFECTION

  2019cites this paper
• Comparison of real-world effectiveness between valsartan and non-RAS inhibitor monotherapy on the incidence of new diabetes in Chinese hypertensive patients: An electronic health recording system based study

  2019cites this paper
• Blood Pressure Control and the Association With Diabetes Mellitus Incidence

  2019cites this paper
• Pancreatic Blood Flow with Special Emphasis on Blood Perfusion of the Islets of Langerhans.

  2019cites this paper
• Hyperkalemia in the Hypertensive Patient

  2018cites this paper
• A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes.

  2018cites this paper
• In vivo efficacy of Dialium guineense fruit pulp on hemeoxygenase-1 and angiotensin converting enzyme in experimental diabetes

  2018influential citation
• Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study

  2018cites this paper
• Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities

  2018cites this paper
• Effect of Vitamin C and Dialium guineense Fruit Pulp Activity on HO-1, Insulin Secretion and Ace in Experimental Diabetes

  2018cites this paper
• Blood pressure-lowering agents response : a systematic review and genome wide study

  2017cites this paper
• Inhibition of the Renin–Angiotensin System: How Far Have We Come?

  2017cites this paper
• Longitudinal Evaluation and Meta-analysis of Clinical Articles on the Antihypertensive Effects of Incretin-related Drugs

  2017cites this paper
• Estrogen attenuates AGTR1 expression to reduce pancreatic β-cell death from high glucose

  2017cites this paper
• Comparing six antihypertensive medication classes for preventing new‐onset diabetes mellitus among hypertensive patients: a network meta‐analysis

  2017cites this paper
• The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension.

  2017cites this paper
• Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

  2017cites this paper
• Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

  2017cites this paper
• Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study

  2016cites this paper
• Effects of antihypertensive drugs losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension combined with isolated impaired fasting glucose

  2016cites this paper
• Angiotensin-converting enzyme inhibitors reduce oxidative stress intensity in hyperglicemic conditions in rats independently from bradykinin receptor inhibitors

  2016cites this paper
• Effects of telmisartan and olmesartan on insulin sensitivity and renal function in spontaneously hypertensive rats fed a high fat diet.

  2016cites this paper
• The role of dietary potassium in hypertension and diabetes

  2016cites this paper
• Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

  2016cites this paper
• The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

  2016cites this paper
• Pathophysiological Mechanisms and Correlates of Therapeutic Pharmacological Interventions in Essential Arterial Hypertension.

  2016cites this paper
• Modulation of glucose metabolism by the renin-angiotensin-aldosterone system.

  2015cites this paper
• Mutations in LRRK2 potentiate age-related impairment of autophagic flux

  2015cites this paper
• Preserving Residual Renal Function in Dialysis: What We Know

  2015influential citation
• Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease

  2015cites this paper
• Clinical impact of acute hyperglycemia on development of diabetes mellitus in non-diabetic patients with acute myocardial infarction.

  2014cites this paper
• Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients.

  2014cites this paper
• Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism

  2014cites this paper
• Is there U-turn from insulin back to pills in diabetes?

  2014cites this paper
• Neurohormonal regulation and improvement in blood glucose control: reduction of insulin requirement in patients with a nonpulsatile ventricular assist device.

  2014cites this paper
• Constitutive activation of the renin-angiotensin system reduces visceral fat and improves glucose tolerance in mice

  2014cites this paper
• Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis

  2014cites this paper
• Prevention of type 2 diabetes; a systematic review and meta‐analysis of different intervention strategies

  2014cites this paper
• New-Onset Diabetes in Heart Failure Patients: A Complex Relationship with Clinical Implications

  2014cites this paper
• Cardiogenic diabetes

  2013cites this paper
• Insulin resistance, chronic heart failure and potential treatment

  2013cites this paper
• Targeted Deletion of Murine CEACAM 1 Activates PI3K-Akt Signaling and Contributes to the Expression of (Pro)Renin Receptor via CREB Family and NF-&kgr;B Transcription Factors

  2013cites this paper
• Improved Glucose-Stimulated Insulin Secretion by Selective Intraislet Inhibition of Angiotensin II Type 1 Receptor Expression in Isolated Islets of db/db Mice

  2013cites this paper
• Nox as a target for diabetic complications.

  2013cites this paper
• Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.

  2013cites this paper
• De la teoría a la práctica: manejo de la hipertensión en casos concretos de la práctica diaria Ejercicio de autoevaluación

  2013cites this paper
• AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ

  2013cites this paper
• Antihypertensive and Metabolic Effects of Angiotensin Receptor Blocker/Diuretic Combination Therapy in Obese, Hypertensive African American and White Patients

  2013cites this paper
• [Hypertension in women].

  2013cites this paper
• Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act.

  2013cites this paper
• Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure

  2013cites this paper
• Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry

  2012cites this paper
• Post-marketing surveillance study of valsartan/amlodipine combination in Taiwanese hypertensive patients

  2012cites this paper
• Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome

  2012cites this paper
• Microvascular responsiveness in obesity: implications for therapeutic intervention

  2012cites this paper
• The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7).

  2012cites this paper
• Telmisartan-induced eNOS gene expression is partially independent of its PPAR-gamma agonist property.

  2012cites this paper
• The Role of Angiotensin Converting Enzyme (ACE) 2 in a Murine Model of Insulin Resistance and Albuminuria

  2012influential citation
• Elevated circulating aldosterone and platelet activity in overweight/obese young adults: Roles in vascular remodeling and cardiometabolic health

  2012cites this paper
• Hipertensión arterial: hechos esenciales

  2012cites this paper
• Link between the renin–angiotensin system and insulin resistance: Implications for cardiovascular disease

  2012cites this paper
• Pathophysiologic therapeutic targets in hypertension: a cardiological point of view

  2012cites this paper
• Potassium and risk of Type 2 diabetes

  2011cites this paper
• Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.

  2011cites this paper
• Microvascular actions of insulin : studies on the interaction with angiotensin II and on the postprandial state

  2011cites this paper
• Telmisartan protects against insulin resistance by attenuating inflammatory response in rats

  2011cites this paper
• Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices

  2011cites this paper
• An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (“Polypill”) in People with Raised Cardiovascular Risk

  2011cites this paper
• Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.

  2011cites this paper
• Idiosyncratic and Uncommon Drug Effects

  2011cites this paper
• Risk Reduction in the Diabetic Patient

  2011cites this paper
• The interplay between glycaemia and cardiovascular disease

  2011influential citation
• Plasma Aldosterone Levels and Development of Insulin Resistance: Prospective Study in a General Population

  2011cites this paper
• Telmisartan protects against insulin resistance by attenuating inflammatory response in rats

  2011cites this paper
• An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill ( ‘ ‘ Polypill ’ ’ ) in People with Raised Cardiovascular Risk

  2011cites this paper
• Review article: pancreatic renin–angiotensin systems in health and disease

  2011cites this paper
• Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals.

  2011cites this paper
• Hypertension 2010: what was new for the cardiologist?

  2010cites this paper
• Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?

  2010cites this paper